(Total Views: 517)
Posted On: 06/05/2022 11:37:47 PM
Post# of 148878
Simple questions for my simple mind:
1. Have we learned anything new at the ASCO meeting re: Leronlimab's safety or efficacy that we haven't already known?
2. Have we learned anything new about a competing drug that outperforms - or possibly could outperform - Leronlimab in safety and/or efficacy?
3. What is the next step for Cytodyn in the cancer arena; are we awaiting some medical journal to publish or critique our results? Are we waiting on the FDA to reconsider our breakthrough designation? Are we waiting to hear if we are still treating those 28 patients (or however many are still alive)? And what about the MD Anderson center at the Univ of Texas, are we doing anything with them?
Any answers most appreciated, and may God Bless America. And Cytodyn!
1. Have we learned anything new at the ASCO meeting re: Leronlimab's safety or efficacy that we haven't already known?
2. Have we learned anything new about a competing drug that outperforms - or possibly could outperform - Leronlimab in safety and/or efficacy?
3. What is the next step for Cytodyn in the cancer arena; are we awaiting some medical journal to publish or critique our results? Are we waiting on the FDA to reconsider our breakthrough designation? Are we waiting to hear if we are still treating those 28 patients (or however many are still alive)? And what about the MD Anderson center at the Univ of Texas, are we doing anything with them?
Any answers most appreciated, and may God Bless America. And Cytodyn!
(4)
(0)Scroll down for more posts ▼
